Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

References

• DeVita VT, Jr, Hellman S, Rosenberg SA. Cancer: Principles & Practice of Oncology7th edition. Lippincott Williams and Wilkins, Philadelphia 2004
   Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907–13
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigen-mediating response. Ann Surg 1998; 228: 307–19
   PubMed Web of Science ®Google Scholar
• Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl 1)S55–7
   PubMed Web of Science ®Google Scholar
• Thompson JA, Figlin RA, Sifri-Steele C, et al. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003; 9: 3562–70
   PubMed Web of Science ®Google Scholar
• Visonneau S, Cesano A, Porter DL, et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res 2000; 6: 1744–54
   PubMed Web of Science ®Google Scholar
• Miller J. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29: 1157–68
   PubMed Web of Science ®Google Scholar
• Tonn T, Becker S, Esser R, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535–44
   PubMed Web of Science ®Google Scholar
• Tam YK, Martinson JA, Doligosa K, Klingemann H-G. Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003; 5: 259–72
   PubMed Web of Science ®Google Scholar
• Yan Y, Steinherz P, Klingemann H-G, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998; 4: 2859–68
   PubMed Web of Science ®Google Scholar
• Tam YK, Miyagawa B, Ho VC, Klingemann HG. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8: 281–90
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotz MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 1985; 313: 1485–92
   PubMed Web of Science ®Google Scholar
• Benyunes MC, Massumoto C, York A, et al. Interleukin-2 with or without lymphokine-activated killer cell as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159–63
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622–32
   PubMed Web of Science ®Google Scholar
• Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002; 23: 438–44
   PubMed Web of Science ®Google Scholar
• Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835–8
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051–7
   PubMed Web of Science ®Google Scholar
• Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998; 82: 1585–92
   PubMedGoogle Scholar
• Berman J, Harland S. Hypoglycemia caused by secretion of insulin-like growth factor 2 in a primary renal cell carcinoma. Clin Oncol (R Coll Radiol) 2001; 13: 367–9
   Google Scholar
• Silverman P, Distelhorst CW. Metabolic emergencies in clinical oncology. Semin Oncol 1989; 16: 504–15
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, et al. Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 2005; 100: 7–13
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–100
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100: 1265–73
   PubMed Web of Science ®Google Scholar
• Mueller, T, Uherek, C, Maki, G, , et al. Expression of a CD20-specific antigen receptor enhances activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother, in press.
   Google Scholar